Carcinoembryonic antigen (CEA antibody) reacts with CEA and CEA-like proteins such as NCA (nonspecific cross-reacting antigen), NCA2 and biliary glycoprotein (BGP1). In all tissues, the NCA of neutrophil granulocytes are stained positive. CEA has been reported to mark adenocarcinoma of the stomach, colon, lung and pancreas; CEA is weakly or occasionally positive (less than 10%) for prostate cancer, bladder cancer and hepatoma. CEA is negative for squamous cell carcinoma of the skin and esophagus, mesothelioma, lymphoma, melanoma and sarcoma.
|Download Data Sheet
|Download RUO Data Sheet for International
|Download SDS Sheet
Regulatory Notice: Biocare’s IVD-labeled products comply with US-FDA and European IVDD regulation. Other regions may have additional requirements for such labeling, please contact your local distributor.
1. Sheahan K, et al. Am J Clin Pathol. 1990 Aug; 94(2):157-64.
2. Nap M, ten Hoor KA, Fleuren GJ. Am J Clin Pathol. 1983 Jan; 79(1):25-31.
3. Nap M, et al. Am J Clin Pathol. 1984 Nov; 82(5):526-34.
4. Selby WL, Nance KV, Park HK. Mod Pathol. 1992 Jul; 5(4):415-9.